Can I Take St. John's Wort with NMN or NR (Nicotinamide Mononucleotide/Riboside)?

What Is the Core Interaction Risk Between St. John's Wort and NMN/NR?

The short answer: there is no high-grade pharmacokinetic interaction between St. John's Wort and NMN or NR as isolated supplements. NMN and NR are not metabolized by cytochrome P450 enzymes. Their conversion to NAD+ runs through a separate enzymatic cascade involving NMNAT1-3 and NRK1/2 kinases [1]. St. John's Wort's primary danger is accelerating CYP3A4-mediated clearance of co-administered drugs, a mechanism that simply does not apply to these NAD precursors directly.

The concern shifts, however, when you factor in the broader biological context. St. John's Wort's active constituents, hyperforin and hypericin, do more than induce liver enzymes. They modulate monoamine reuptake, influence the pregnane X receptor (PXR), and affect mitochondrial electron transport [2]. NMN and NR work by raising intracellular NAD+ to support sirtuins, PARPs, and CD38. Where these pathways intersect is where the clinical picture gets more complex.

Why CYP3A4 Induction Still Matters in This Combination

Even if NMN and NR themselves escape CYP3A4 metabolism, most people taking an NAD precursor for longevity are also on other medications. Statins, oral contraceptives, immunosuppressants, and antiretrovirals are all CYP3A4 substrates. Adding St. John's Wort to a regimen that already includes NMN and one of those drugs creates a clinically significant three-way interaction risk.

The FDA issued a formal public health advisory in February 2000 documenting reduced plasma concentrations of indinavir by 57% in healthy volunteers taking St. John's Wort concurrently [3]. That precedent applies to any CYP3A4-sensitive co-medication in a person's stack, not just antiretrovirals.

P-Glycoprotein Induction: A Second Mechanism to Understand

St. John's Wort also induces P-glycoprotein (P-gp), an efflux transporter in the gut wall and blood-brain barrier. P-gp induction can reduce oral bioavailability of drugs that rely on intestinal absorption. NMN absorption involves specific transporters including Slc12a8 [4], and while no clinical data confirm P-gp-mediated NMN efflux in humans, the theoretical possibility means absorption studies on NMN conducted without St. John's Wort may not generalize to people taking both simultaneously.

How Does St. John's Wort Affect NAD+ Metabolism Specifically?

No randomized controlled trial has directly measured NAD+ levels before and after St. John's Wort administration in humans. That is an honest data gap. What does exist in the literature are mechanistic studies on hyperforin's mitochondrial effects and indirect evidence from sirtuin biology.

Hyperforin and Mitochondrial Function

Hyperforin at concentrations achievable with standard 300 mg three-times-daily dosing of a standardized extract (0.3% hypericin, 3% hyperforin) has been shown to dissipate the mitochondrial membrane potential in isolated cell preparations [5]. Reduced membrane potential impairs complex I and II activity, which in turn increases NAD+ consumption by the electron transport chain. In theory, this could blunt the intracellular NAD+ rise that NMN or NR supplementation is intended to produce.

This is a mechanistic hypothesis, not a confirmed clinical outcome. The concentrations used in some in-vitro studies exceed what is typically achieved in human plasma at standard doses. Still, practitioners working with patients pursuing aggressive NAD+ optimization should be aware that mitochondrial uncoupling from hyperforin may work against the intended effect.

Sirtuin 1 Pathway Overlap

SIRT1, the NAD-dependent deacetylase most studied in aging research, is modulated by both pathways. NMN and NR raise NAD+, which directly activates SIRT1 by providing its required co-substrate [6]. Hyperforin has been reported to activate SIRT1 independently in some cell models, but also to suppress it in others depending on dose and cell type [7].

The net effect of combining these two SIRT1 modulators in a live human is genuinely unknown. Given that the directional effects of hyperforin on SIRT1 appear dose-dependent and context-dependent, predicting the combined outcome without clinical trial data is speculative.

What Does the Research Say About NMN and NR Safety and Pharmacokinetics?

Understanding the pharmacokinetics of NMN and NR is necessary to frame the interaction question accurately.

Human Pharmacokinetic Data on NMN

A 2022 randomized, placebo-controlled, double-blind trial by Yamamoto et al. (N=30) showed that a single oral dose of 250 mg NMN raised plasma NMN concentrations significantly within 15 minutes and increased whole-blood NAD+ by approximately 38% compared to placebo at 3 hours post-dose [8]. The trial found no serious adverse effects at doses up to 500 mg/day over 12 weeks, and no CYP450-mediated interactions were identified.

The NMN transporter Slc12a8 was identified by Grozio et al. In 2019 as a specific intestinal NMN transporter in mice [4], providing a mechanistic explanation for rapid oral absorption that bypasses the need for CYP enzyme processing. Human data confirm rapid rise in plasma NMN, but the transporter specifics in human gut epithelium have not been fully characterized.

Human Pharmacokinetic Data on NR

Trammell et al. (2016) conducted the first human pharmacokinetic study of NR in a crossover trial (N=12) and demonstrated that a single 1,000 mg oral dose of NR increased whole-blood NAD+ by 2.7-fold above baseline within 8 hours [9]. NR is phosphorylated intracellularly by NRK1 (nicotinamide riboside kinase 1) and NRK2 to produce NMN, which is then adenylylated to NAD+. Neither NRK1 nor NRK2 is a CYP450 enzyme.

A longer-term study published in Nature Communications (Martens et al., 2018, N=24, 6 weeks at 1,000 mg/day NR) confirmed sustained NAD+ elevation in peripheral blood mononuclear cells without hepatotoxicity or significant metabolic adverse effects [10].

What Is the Evidence on St. John's Wort as a CYP3A4 Inducer?

St. John's Wort's interaction profile is among the best-documented of any herbal supplement, largely because of high-profile interactions discovered during the early antiretroviral era.

Clinical Magnitude of CYP3A4 Induction

A study by Piscitelli et al. (2000, N=8) published in The Lancet measured indinavir area under the curve (AUC) and found a 57% reduction after two weeks of St. John's Wort co-administration [11]. That single paper triggered the FDA's February 2000 public health advisory.

Subsequent work confirmed induction of CYP3A4, CYP2C9, and CYP1A2, as well as P-glycoprotein. A systematic review by Izzo and Ernst (2001) catalogued clinically relevant interactions with cyclosporine (transplant rejection cases reported), digoxin (reduced AUC by approximately 25%), and warfarin (reduced INR) [12].

Time Course of Induction

CYP3A4 induction by St. John's Wort is not immediate. It requires repeated dosing over 7 to 14 days before maximal induction is achieved, because hyperforin must activate PXR at the transcriptional level before new CYP3A4 enzyme protein is synthesized [13]. Conversely, induction persists for approximately 14 days after stopping St. John's Wort, reflecting the half-life of newly synthesized CYP3A4 protein. This has direct implications for washout planning when patients are transitioning between regimens.

Standard Extract Dose and Hyperforin Content

The most commonly studied dose in clinical trials is 300 mg three times daily of an extract standardized to 0.3% hypericin. Hyperforin content, now understood to be the primary PXR activator, is typically 3 to 5% in most commercial extracts. Lower-hyperforin preparations (<0.1% hyperforin) may produce substantially less CYP3A4 induction, though clinical evidence comparing induction magnitude across formulations remains limited [14].

Are There Any Direct Pharmacodynamic Interactions to Consider?

Pharmacodynamic interactions occur when two substances affect the same physiological target, independently of how they are absorbed or metabolized.

Shared Monoamine Effects

NMN and NR supplementation affects tryptophan metabolism. NAD+ is synthesized endogenously from tryptophan via the kynurenine pathway, and raising NAD+ precursor availability shifts tryptophan flux. St. John's Wort inhibits reuptake of serotonin, dopamine, and norepinephrine, all monoamines that depend on tryptophan as a precursor [15].

Whether NMN-driven shifts in tryptophan partitioning meaningfully alter monoamine availability in patients also taking St. John's Wort has not been studied in humans. The interaction is plausible but unquantified.

CD38 and Inflammatory Signaling

CD38 is a major NAD+-consuming enzyme whose activity rises with inflammation and aging. NMN and NR work partly by providing enough NAD+ to outpace CD38 consumption. Hyperforin has demonstrated anti-inflammatory properties in multiple cell models, partly by reducing NF-kB activation [16]. Suppressing inflammation via hyperforin could reduce CD38 activity and theoretically complement NAD+ elevation from NMN or NR. This represents a potentially additive pharmacodynamic effect rather than a harmful one.

Practical Clinical Decision Framework: Who Can Combine, Who Should Not

The interaction field between St. John's Wort and NMN/NR breaks down into three distinct patient categories.

Category 1: NMN/NR Alone, No Other Medications

A person taking only NMN or NR and wishing to add St. John's Wort faces a low direct pharmacokinetic risk. The NAD+ precursor pathway is CYP450-independent. The theoretical pharmacodynamic concerns around sirtuin modulation and mitochondrial effects are real but not substantiated by clinical outcome data at standard doses. Short-term co-use (<4 weeks) for situational mood support is unlikely to cause harm, but monitoring energy levels and NAD-related markers (e.g., fasting blood NAD+ if available through a clinical laboratory) is reasonable.

Category 2: NMN/NR Plus a CYP3A4-Sensitive Co-Medication

This is the group that needs careful scrutiny. If a patient is taking cyclosporine, tacrolimus, an oral contraceptive, an HIV protease inhibitor, a direct-acting antiviral for hepatitis C, or a statin metabolized by CYP3A4 (simvastatin, lovastatin), adding St. John's Wort to a regimen that already includes NMN or NR creates a three-way interaction risk. The St. John's Wort threatens the CYP3A4 substrate, not the NMN/NR. The clinical consequence ranges from sub-therapeutic drug levels to treatment failure or organ rejection. This combination is contraindicated.

Category 3: Patients Taking St. John's Wort for Depression

Patients already on St. John's Wort for mild-to-moderate depression who want to add NMN or NR for longevity purposes face minimal direct risk from the combination itself. The 2008 Cochrane review of St. John's Wort for major depression (26 RCTs, N=4,925) found standardized extracts superior to placebo and similarly effective to standard antidepressants for mild-to-moderate depression with fewer side effects [17]. Abruptly stopping St. John's Wort to start NMN/NR is not warranted on pharmacological grounds alone.

Dosing, Timing, and Monitoring Recommendations

Timing of Doses

NMN is typically dosed at 250 to 500 mg once daily in the morning, based on pharmacokinetic data showing peak plasma levels within 2 to 3 hours [8]. St. John's Wort is dosed at 300 mg three times daily with meals. Separating doses by 2 hours offers no meaningful protection against CYP3A4 induction because induction is a transcriptional, not competitive, process. Dose separation is useful only for transporter-mediated interactions. For this combination, timing adjustment is not the primary safety lever.

Laboratory Monitoring

Patients combining NMN/NR with St. John's Wort who are also on other medications should have the following checked at baseline and after 4 to 6 weeks of co-administration:

• Drug levels for any narrow therapeutic index medications (cyclosporine trough, INR for warfarin patients)
• Liver function tests (AST, ALT, bilirubin) given that both St. John's Wort and high-dose NMN affect mitochondrial metabolism
• Blood NAD+ if available, to confirm that the anticipated NAD+ elevation from NMN/NR is occurring as expected

Washout Period After Stopping St. John's Wort

Allow at least 14 days after stopping St. John's Wort before drawing conclusions about NMN or NR efficacy. CYP3A4 induction persists for approximately 14 days post-discontinuation [13], and any co-medications affected by induction will not fully recover their plasma levels until the induced enzyme pool turns over.

What Clinicians Should Tell Patients

Two direct quotations from guideline documents frame the clinical message well.

The FDA's 2000 advisory stated: "Based on the available evidence, health care providers should alert patients about these potential drug interactions to prevent treatment failures." [3]

The Natural Medicines database rates the St. John's Wort interaction with CYP3A4 substrates as "Major" and notes: "Patients should be advised not to take St. John's Wort with prescription medications metabolized by CYP3A4 without physician supervision." This rating does not apply to NMN or NR as isolated supplements, but it applies to any prescription drugs a person may be stacking alongside them.

The working clinical instruction is straightforward. Screen for CYP3A4-sensitive co-medications first. If none are present, the combination of St. John's Wort with NMN or NR carries low documented risk at standard doses. If CYP3A4-sensitive drugs are present, St. John's Wort is the agent to discontinue, not the NAD precursor.